1. Home
  2. BIOA

as of 02-24-2026 4:00pm EST

$21.56
+$0.21
+0.98%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Founded: 2015 Country:
United States
United States
Employees: 64 City: EMERYVILLE
Market Cap: 856.3M IPO Year: N/A
Target Price: $40.50 AVG Volume (30 days): 601.6K
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.88 - $24.00 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -58.12%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Latest BioAge Labs Inc. News

BIOA Breaking Stock News: Dive into BIOA Ticker-Specific Updates for Smart Investing

All BIOA News

Share on Social Networks: